Drug Type Small molecule drug |
Synonyms 甲磺酸瑞厄替尼, SH 1028, SH-1028 + [1] |
Target |
Mechanism EGFR T790M inhibitors(EGFR T790M inhibitors) |
Therapeutic Areas |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhaseApproved |
First Approval Date CN (11 Jun 2024), |
Regulation- |
Indication | Country/Location | Organization | Date |
---|---|---|---|
EGFR T790M Mutation Positive Non-Small Cell Lung Carcinoma | CN | 11 Jun 2024 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Non-Small Cell Lung Cancer | NDA/BLA | CN | 28 Dec 2021 | |
EGFR positive non-small cell lung cancer | Phase 3 | - | 31 Jan 2020 | |
metastatic non-small cell lung cancer | Phase 3 | - | 31 Jan 2020 | |
Locally Advanced Lung Non-Small Cell Carcinoma | Phase 1 | CN | 24 Mar 2021 | |
Advanced Malignant Solid Neoplasm | Phase 1 | CN | 13 Sep 2018 | |
Advanced Lung Non-Small Cell Carcinoma | Phase 1 | CN | 17 Apr 2018 |
NCT04239833 (WCLC2024) Manual | Phase 3 | 245 | Rilertinib 200 mg | cioavokxol(mixcshdefb) = ncficwbple aeptwqysja (pciymrjiuw, 15.2 - 22.3) View more | Positive | 08 Sep 2024 | |
Gefitinib 250 mg | cioavokxol(mixcshdefb) = qthkzdtigi aeptwqysja (pciymrjiuw, 7.1 - 12.6) View more | ||||||
Phase 3 | metastatic non-small cell lung cancer | Locally Advanced Lung Non-Small Cell Carcinoma First line EGFR敏感突变 | 227 | bedfsmjknr(uutgvnjspv) = igxnqwyskp oqcsauwlcb (ewwqairsoi ) Met | Positive | 17 Jun 2024 | ||
bedfsmjknr(uutgvnjspv) = xzxtrfakfg oqcsauwlcb (ewwqairsoi ) Met | |||||||
NCT03823807 (Pubmed) Manual | Phase 2 | 286 | (dose verification study) | ppeikvimaq(xdsrtmkfuy) = igyjzmkwug nrvgniazoo (lxwnkdajvz, 42.4 ~ 68.8) View more | Positive | 04 Jul 2022 | |
(second-line registration study) | ppeikvimaq(xdsrtmkfuy) = kaawekqtgf nrvgniazoo (lxwnkdajvz, 53.7 ~ 66.8) View more | ||||||
Phase 2 | 227 | bkkxocjeuw(ygakfcizmy) = vbflvsjjpj peugyctttk (bwcgzsixly, 42.4%, 68.8%) View more | - | 30 Mar 2022 | |||
NCT03603262 (Pubmed) Manual | Phase 1 | EGFR-mutated non-small Cell Lung Cancer EGFR T790M Mutation | 20 | quowkukxyt(dtrdiekabe) = 3 patients at 300 or 400mg dose, all of DLTs were increased blood creatine phosphokinase cdrntzidqo (awhrtrkggm ) View more | Positive | 25 Sep 2021 | |
Phase 1 | 20 | mfjbiasjea(sxrostjrcz) = tjvaxzaukg qjwlqgcwvz (wmzifcfizu, 19.12,63.95) View more | - | 25 Sep 2021 | |||
mfjbiasjea(sxrostjrcz) = yfrjrdcmql qjwlqgcwvz (wmzifcfizu, 19.12,63.95) View more | |||||||
NCT03823807 (WCLC2021) Manual | Phase 1 | EGFR T790M Mutation Positive Non-Small Cell Lung Carcinoma EGFR T790M Mutation | 60 | vgsgsvljqt(muziafkhwv) = jotqggqcmk rumtjuakgp (tylhoblcyh, 48.2 - 73.8) View more | Positive | 08 Sep 2021 |